All News

Advance growth

Practical use of JAK inhibitors in select groups in Axial SpA

d Antoni Chan, MD, PhD

A new treatment for AxSpA that has come on the scene are JAK inhibitors. In clinic, considerations for JAKi use are body mass index, smoking status, prior use of biologics and patients with high inflammatory states such as high CRP and inflammatory change on MRI scan of the spine and sacroiliac joints. There are further studies at #ACR22 which help answer these questions.

Read Article
question-mark-1872634_640.jpg

Do biologics help taper steroids in Adult Still’s Disease?

d Bella Mehta, MBBS, MS

A Japanese large scale claims data study was able to collect 5-year data to study the treatment patterns in Still’s. In May 2019, intravenous tocilizumab was approved in Japan for Still’s disease. The study was designed to see patterns of steroid exposure before and after the approval of this therapy.

Read Article
lupus.jpg

Anifrolumab shows long-term promise in patients with lupus

d EurekAlert!

Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease.

Read Article
pso.arm_.JPG

“Hey PRESTO!” – Early identification of psoriatic arthritis

d Patricia Harkins, MD

Despite a wealth of treatment options, a number of notable unmet needs remain in PsA, most notably the significant diagnostic delay that many patients endure. We are all aware that those with psoriatic skin disease are the most at risk cohort for PsA. Identifying patients with psoriasis who have, or are at increased risk of PsA, appears to be the low hanging fruit that we just can’t fully seem to grasp.

Read Article
covid coronavirus virus

Long COVID and Rheumatic Disease

d Akhil Sood, MD

The COVID-19 pandemic has had a significant impact worldwide particularly among those who are immunocompromised. Numerous studies have highlighted the increased risk of acute SARS-CoV-2 infection among patients with rheumatic diseases (RD).

Read Article
What's the difference between RA and PsA on hand MRI? Removing our cognitive biases, here's what a neural network has to say (not hard to see the power of this work) ABST0242 @LkasDer @maier_ak #ACR22 @DrCMcMaster @RheumNow https://t.co/TqS6xUZNtl
David Liew drdavidliew ( View Tweet)
Abst0327 #ACR22 SMART-SLE Monitoring Some SLE patients with +dsDNA have persistent positivity, others have fluctuations Anti-dsDNA in persistently positive HR 1.56 for flare risk Change (up or down!) in dsDNA more than 2x prior visit for fluctuating patients: HR 1.43 @RheumNow https://t.co/YwDPTYWPLu
Eric Dein ericdeinmd ( View Tweet)
It's always amazed me adalimumab & abatacept, have very different MOA but similar efficacy in RA - on a population level. Not for individuals, though. Surely we can pick the winners better? Lovely biomarker work from a H2H RCT ABST0244 #ACR22 @RheumNow https://t.co/qVttIZSQtc
David Liew drdavidliew ( View Tweet)
Abst0324 #ACR22 How close are we to measuring Interferon Signature in clinical practice? NCounter and BioFire assays studied - correlated well we each other Genes: IFI27, IFI44L, IFIT1, RSAD2 SLE higher than RA or FMS, but does not correlate with SLE activity @RheumNow https://t.co/izpFtj9Pcd
Eric Dein ericdeinmd ( View Tweet)
Abst0326 #ACR22 Anti-Mitochondrial Ab in SLE Whole mitochondrial (AwMA), AmtDNA or AmtRNA - higher in SLE compared to controls AwMA predictive of death, AmtDNA and AmtRNA predictive of nephritis @Rheumnow https://t.co/d98HSHnJVE
Eric Dein ericdeinmd ( View Tweet)
What if my patient with RA or PsA gets pregnant? @RheumNow #ACR22 Abstract #1786; 34 women 👶 Disease scores improved during #pregnancy and increased #postpartum 👶20-27% of women required a cesarean delivery 👶mean delivery 39-40 weeks gestation 👶 1 NICU admission https://t.co/qYPaB6TcDJ
Catherine Sims, MD DrCassySims ( View Tweet)
JAK inhibitors in RA: does their performance vary in the real world? @opal_ltd 🇦🇺: n= 5900 JAKi-treated RA pts, 2015-2021 upa is relatively new in Australia, but amazing how bari and tofa are so similar (same with the data on switching reason too) ABST0274 #ACR22 @RheumNow https://t.co/63PrRVAzk5
David Liew drdavidliew ( View Tweet)
Abst0328 #ACR22. Predicting UCTD to CTD Meta-Analysis Factors for SLE transition: younger age, serositis, dsDNA SSc transition: puffy finger, NFC, or SSc antibodies No studies wo moderate or high risk of bias Limited studies on biomarkers for SLE, need more studies @Rheumnow https://t.co/GofGF8TkCx
Eric Dein ericdeinmd ( View Tweet)
Time check!⌚🦉 This roaming clockface helps me navigate through time zones while attending #ACR22 ✈️virtually jetlagged but having fun!🤓 @RheumNow @rheumarhyme @doktora_ging #RheumPix https://t.co/HgTcIyw7ej
sheila RHEUMarampa ( View Tweet)
Infections in JAKi v TNFi in RA We've seen ORAL Surveillance data What about East Asian pts, with enriched zoster risk? National KOR🇰🇷 insurance data: Bacterial: equal Opportunistic: TNFi worse Zoster: JAKi worse serious zoster a lot more common here! ABST0302 #ACR22 @RheumNow https://t.co/lxsbY1Nf9N
David Liew drdavidliew ( View Tweet)
“Conflict, crisis and resolution make a story. A good story has drama where there is desire with danger.” @cuttingforstone author, Dr. Verghese noted the COVID19 #pandemic has all of these elements. It is a good story, but we don’t know the resolution. @Rheumnow #ACR22 https://t.co/Tomev2SYcT
TheDaoIndex KDAO2011 ( View Tweet)
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

Let’s do this #ACR22 ⁦@RheumNow⁩ #rheumpix https://t.co/zTx4TynK44
Eric Dein ericdeinmd ( View Tweet)
AS, Lupus and Subclinical RA: What I'm looking forward to at #ACR22 There are three areas that always draw my attention each conference and this time is no different... https://t.co/1h7NRgcqCm https://t.co/9P1UwrmjxW

Links:

Dr. John Cush RheumNow ( View Tweet)
Progression from non-radiographic to radiographic AxSpA is not the norm ● 16% progress over 5 years, 10-25% over 10 years ● Syndesmophytes in 20% over 4 years ● Male, MRI+ at baseline, response to NSAIDs are predictors of progression Jose U Scher, Review @RheumNow #ACR22 https://t.co/FatodINTfn
Dr. Antoni Chan synovialjoints ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×